RxDoctor Payments Data

Thomas Jones, MD

Ophthalmology · Everett, WANPI 1578587002

Payments from drug & device makers

$967in general payments, 2019–2025

Across 40 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$182
  • Alcon$160
  • Sun Pharmaceutical Industries Inc.$127
  • Oyster Point Pharma, Inc.$83
  • Synergeyes, Inc.$80
  • AbbVie$67
  • plus $270 from 9 others

What the payments were for

  • Food & beverage$91194%
  • Gifts$566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$967 in reported general payments places this provider in the 50th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$133,874
Medicare patients
523
Services billed
993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$64,580
LumiganBimatoprost42$28,304
RocklatanNetarsudil Mesylat/Latanoprost36$28,009
CombiganBrimonidine Tartrate/Timolol40$16,419
Latanoprost522$8,217
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$5,427
SimbrinzaBrinzolamide/Brimonidine Tart11$4,296
Cyclosporine12$2,986
Prednisolone Acetate84$2,799
Timolol Maleate220$2,665
Ketorolac Tromethamine80$2,065
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat122$1,913
MoxifloxacinMoxifloxacin Hcl81$1,879
Fluorometholone28$1,854
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$67$109,303130 claims
AlconSimbrinza$160$4,29611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →